This article is Part 2 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1(link to article) provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class.
This short article takes a deeper look into the 2021 IPOs by technology and therapeutic class (small molecule vs. biotechnology) across the five most prevalent therapeutic areas: oncology, CNS, immunology, genetic diseases, and infectious diseases/other.
request a trial
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
